The evaluation of the effects of CAsein hydroLysate containing milk-derived Peptides on vascular function and blood pressure

The evaluation of the effects of CAsein hydroLysate containing milk-derived Peptides on vascular function and blood pressure - CALP study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000027726

Enrollment

Registered

2017-08-01

Start date

2017-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

CAsein hydroLysate containing milk-derived Peptides placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: casual blood pressure under treatment <150/90 mmHg

Exclusion criteria

Exclusion criteria: cardiovascular disease/ malignancy allergy for milk atrial fibrillation chronic kidney disease

Design outcomes

Primary

Measure	Time frame
home blood pressure, blood pressure, vascular function	—

Secondary

Measure	Time frame
renal function	—

Countries

Japan

Contacts

Public ContactHirofumi Tomiyama

Tokyo medical university cardiology

tomiyama@tokyo-med.ac.jp03-3342-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026